SG Americas Securities Boosts Stake in Taysha Gene Therapies

Investment firm increases holdings by over 2,200% in biotech firm focused on rare CNS disorders

Apr. 2, 2026 at 9:03am

Got story updates? Submit your updates here. ›

SG Americas Securities LLC significantly increased its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the fourth quarter, boosting its holdings by 2,271.8% to 781,474 shares. The investment firm now owns approximately 0.29% of the Dallas-based biotech company, which is developing gene therapies for rare central nervous system disorders.

Why it matters

Taysha Gene Therapies is a clinical-stage biotech firm working on innovative gene therapy treatments for life-threatening pediatric CNS disorders. The significant increase in SG Americas Securities' stake suggests growing institutional investor confidence in the company's pipeline and future potential.

The details

According to a 13F filing with the SEC, SG Americas Securities acquired an additional 748,525 shares of Taysha Gene Therapies during the fourth quarter, bringing its total holdings to 781,474 shares. This represents a 2,271.8% increase from the previous quarter. The investment firm now owns approximately 0.29% of Taysha's outstanding shares, valued at $4.3 million as of the most recent filing.

  • SG Americas Securities reported the stake increase in its 13F filing for the fourth quarter of 2025.
  • Taysha Gene Therapies is a clinical-stage company founded in 2019 and headquartered in Dallas, Texas.

The players

SG Americas Securities LLC

An investment firm that significantly increased its stake in Taysha Gene Therapies during the fourth quarter of 2025.

Taysha Gene Therapies, Inc.

A clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system.

Got photos? Submit your photos here. ›

The takeaway

The substantial increase in SG Americas Securities' position in Taysha Gene Therapies suggests growing institutional investor confidence in the company's pipeline of gene therapy treatments for rare and life-threatening pediatric CNS disorders. This could signal positive momentum for the biotech firm as it continues to advance its clinical programs.